REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
8.00
+0.48 (6.38%)
May 12, 2025, 3:03 PM - Market open
REGENXBIO Market Cap
REGENXBIO has a market cap or net worth of $400.94 million as of May 12, 2025. Its market cap has decreased by -43.74% in one year.
Market Cap
400.94M
Enterprise Value
292.28M
1-Year Change
-43.74%
Ranking
Category
Stock Price
$8.00
Market Cap Chart
Since September 17, 2015, REGENXBIO's market cap has decreased from $749.30M to $400.94M, a decrease of -46.49%. That is a compound annual growth rate of -6.28%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 9, 2025 | 376.60M | -1.67% |
| Dec 31, 2024 | 383.00M | -51.50% |
| Dec 29, 2023 | 789.70M | -19.57% |
| Dec 30, 2022 | 981.90M | -29.79% |
| Dec 31, 2021 | 1.40B | -17.57% |
| Dec 31, 2020 | 1.70B | 12.32% |
| Dec 31, 2019 | 1.51B | 0.48% |
| Dec 31, 2018 | 1.50B | 45.18% |
| Dec 29, 2017 | 1.04B | 110.87% |
| Dec 30, 2016 | 491.10M | 12.43% |
| Dec 31, 2015 | 436.80M | -41.71% |
View and export this data all the way back to 2015.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 682.08B |
| Johnson & Johnson | 372.82B |
| UnitedHealth Group | 342.98B |
| AbbVie | 339.27B |
| Novo Nordisk | 292.03B |
| Abbott Laboratories | 230.60B |
| Novartis AG | 213.30B |
| AstraZeneca | 211.14B |